Identification of a Serum Three-MicroRNA Signature for Cervical Cancer Diagnosis

0
0
0

Identification of a Serum Three-MicroRNA Signature for Cervical Cancer Diagnosis

Cervical cancer (CC) is the fourth most common cancer in women worldwide, responsible for over 340,000 deaths annually according to the World Health Organization (WHO). While HPV testing and Pap smears have reduced mortality, these tools often yield false results, miss early-stage disease, or require invasive procedures—creating a critical need for non-invasive, accurate diagnostic biomarkers. A 2021 study from researchers at Nanjing Medical University and Fudan University Shanghai Cancer Center offers new hope: a three-microRNA (miRNA) signature in blood serum that could revolutionize CC screening.

The Research Team & Ethics

Led by Min-Min Cao, Qing-Xie Liu, and Wei Zhu (Department of Oncology, First Affiliated Hospital of Nanjing Medical University), the study included collaborators from six departments across Nanjing Medical University and Fudan University Shanghai Cancer Center. It followed ethical guidelines and was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (No. 2016-SRFA-148).

How the Study Worked

The team used a four-stage pipeline to identify and validate their miRNA signature, involving 108 CC patients and 108 healthy controls (NCs) recruited between 2016–2017:

  1. Screening: They pooled 20 CC and 10 NC serum samples to test 174 common circulating miRNAs using an Exiqon qPCR panel. This narrowed down to 29 candidate miRNAs with significant expression differences between CC and NCs.
  2. Training/Testing: They validated these candidates in 30 CC/30 NC (training) and 60 CC/60 NC (testing) groups using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). They normalized miRNA levels to reference genes (e.g., miR-16-5p for serum) to ensure accuracy.
  3. External Validation: The top miRNAs were tested in an independent set of 18 CC/18 NC samples.
  4. Subgroup & Functional Analysis: They evaluated how the signature performed across CC stages (I–IV) and histological types (squamous cell carcinoma vs. adenocarcinoma). They also measured miRNA levels in CC tissues and serum exosomes (cell-derived vesicles) to explore their origin and role in cancer progression.

Key Findings: A Promising Non-Invasive Signature

The team identified three serum miRNAs with consistent, stage-independent differences between CC patients and healthy controls:

  • miR-122-5p and miR-20a-5p: Upregulated (higher levels) in CC serum.
  • miR-133a-3p: Downregulated (lower levels) in CC serum.

When tested individually, each miRNA showed moderate diagnostic ability—measured by the area under the receiver operating characteristic curve (AUC), where 1.0 = perfect accuracy. For example:

  • miR-122-5p: AUC = 0.672 (67.2% accuracy)
  • miR-20a-5p: AUC = 0.681 (68.1% accuracy)
  • miR-133a-3p: AUC = 0.666 (66.6% accuracy)

The breakthrough came when combining all three into a diagnostic panel. Using logistic regression, the panel’s AUC reached 0.816 for the combined training/testing groups—meaning it correctly identified CC patients 81.6% of the time. Even in an independent validation set (18 CC/18 NC), the AUC remained strong at 0.808 (80.8% accuracy).

Why This Matters for Clinical Use

The signature performed reliably across all CC stages (I–IV) with AUC values ranging from 0.661 (stage IV) to 0.722 (stage III). It also did not differ between squamous cell carcinoma and adenocarcinoma—the two most common CC types—making it broadly applicable.

Additional experiments revealed:

  • Tumor Origin: miR-20a-5p was upregulated in CC tissues, suggesting circulating levels come directly from the tumor.
  • Exosomal Role: miR-122-5p and miR-20a-5p were higher in CC exosomes—hinting they may drive cancer progression by signaling between cells.

Bioinformatics analysis linked the miRNAs to critical cancer pathways (e.g., cell cycle, p53 signaling), laying groundwork for future research into their exact mechanisms.

Next Steps & Limitations

While the results are promising, the team emphasizes that larger, multi-center studies are needed to confirm the signature’s effectiveness in diverse populations. The panel is not yet ready for clinical use—but it represents a major step toward non-invasive CC screening that is faster, more accurate, and less stressful than current tools.

Original Study Citation

Cao MM, Liu QX, Zou X, Fan XC, Liu C, Zhang SY, Wang TS, Li CY, Zhang C, Geng XN, Liu P, Zhu W. Identification of a serum three-microRNA signature for cervical cancer diagnosis. Chinese Medical Journal. 2021;134(14):1756–1758. doi:10.1097/CM9.0000000000001327

Was this helpful?

0 / 0